Glucophage is commonly used alongside nutrition changes and physical activity for long-term blood-glucose control. It does not replace insulin and does not stimulate the pancreas to release large amounts of insulin.
Glucophage is used by adults with type 2 diabetes to support long-term blood-glucose control. It is commonly used alongside nutrition changes and physical activity, as part of an individual treatment plan.
Metformin hydrochloride lowers excess glucose production in the liver and improves the body’s response to insulin. This helps the body use available insulin more effectively without stimulating the pancreas to release large amounts of insulin.
Glucophage is not suitable for everyone. It should not be used in people with severe renal impairment or acute conditions that can reduce tissue oxygenation and increase lactic acidosis risk.
This medicine is not for you if you have:
Extra caution is needed with heavy alcohol intake, recurrent vomiting or diarrhoea, fasting, major surgery, severe infection, and medicines that affect kidney function. Pregnancy and breastfeeding require an individual treatment decision because glucose control itself is important, while treatment selection may change during pregnancy.
Digestive effects are the most familiar problem with Glucophage. They are linked to changes in intestinal glucose handling and gut activity, and they often improve after the body adapts.
Common or recognised reactions include:
Taking metformin with food and increasing the dose gradually can reduce these symptoms. Persistent diarrhoea matters because fluid loss can impair kidney function and increase the risk of metformin accumulation.
Long-term metformin use can reduce vitamin B12 absorption in some people. Symptoms of low B12 may include unusual tiredness, a sore or red tongue, pins and needles, numbness, balance problems, or pale skin. The risk increases with longer treatment duration, higher doses, older age, and existing nutritional problems. Clinicians may repeat testing when symptoms or risk factors persist. NICE and MHRA communications support targeted B12 assessment when symptoms or risk factors are present [2].
Lactic acidosis is rare but serious. The risk rises when metformin accumulates because of severe kidney impairment, dehydration, low oxygen states, severe infection, heavy alcohol intake, or significant liver dysfunction.
Urgent symptoms include:
Stop taking the next dose and seek urgent medical care if these symptoms occur, especially when several appear together. Do not attempt to manage suspected lactic acidosis at home with extra fluids or glucose.
Glucophage contains metformin hydrochloride, an oral biguanide used in the management of type 2 diabetes. It does not replace insulin and does not stimulate the pancreas to release large amounts of insulin. Its main effects are reducing hepatic glucose production and improving insulin sensitivity in muscle and other tissues.
Metformin is used when the body still produces insulin but does not respond to it adequately. NICE guidance places metformin among the main medicines used in type 2 diabetes management, with treatment selected according to kidney function, blood-glucose targets, cardiovascular risk, and other medicines [1].
Immediate-release metformin tablets release the active ingredient relatively promptly after swallowing. Modified-release tablets release metformin more gradually and may be prescribed when digestive symptoms occur with immediate-release treatment. The exact administration schedule depends on the strength and formulation supplied.
Glucophage is taken by mouth. The tablet should be swallowed as directed, rather than crushed or chewed when it is a modified-release formulation.
Dosing differs between strengths and between users, so there is no single amount that suits everyone. The prescriber usually starts with a lower schedule and increases it gradually according to glucose results, digestive tolerance, and kidney function.
Practical administration principles include:
A temporary interruption may be required during severe dehydration or around some procedures involving iodinated contrast. The decision depends on kidney function and the procedure, so the prescribing team should provide the specific restart plan.
| Approach | Main action | Main limitation |
|---|---|---|
| Metformin tablets | Reduce liver glucose production and improve insulin sensitivity | Digestive symptoms; kidney function limits use |
| Insulin therapy | Replaces or supplements insulin directly | Hypoglycaemia and weight gain can occur |
| Sulfonylurea therapy | Stimulates insulin release from pancreatic beta cells | Hypoglycaemia and weight gain are possible |
Metformin is often used early because it targets insulin resistance and usually has a low hypoglycaemia risk when taken alone. Insulin becomes essential when pancreatic insulin production is inadequate, during some acute illnesses, or when glucose remains high despite other treatments. Sulfonylureas can lower glucose promptly but stimulate insulin release even when food intake is reduced, which raises the risk of low blood sugar.
The best choice is not determined by glucose alone. Kidney function, heart failure, cardiovascular disease, frailty, pregnancy, weight goals, and the person’s ability to manage multiple medicines all influence treatment selection.
Several habits reduce the benefit of Glucophage or increase avoidable problems:
A missed dose should not be “made up” with two doses together. If several doses have been missed, the prescriber may need to review the schedule rather than simply restarting at the previous amount.
In clinical practice, doctors usually judge metformin by the trend in HbA1c and fasting glucose, not by whether one tablet produces an immediate sensation. Improvement develops over repeated doses and is assessed alongside diet, activity, weight, kidney function, and adherence.
A doctor will also ask about bowel changes, appetite, alcohol intake, contrast scans, and new medicines. These details can alter the risk profile even when the Glucophage dose has not changed. A patient who feels well should still attend planned diabetes reviews because high glucose can remain symptom-free.
One practical point is frequently missed: a normal glucose reading after one meal does not prove that the full treatment plan is working. HbA1c and repeated readings provide a more reliable picture.
Severe renal impairment and current lactic acidosis are clear reasons not to use metformin. Acute dehydration, severe infection with poor circulation, and major oxygen deprivation also require the medicine to be withheld or avoided until the situation is assessed. MHRA safety information available in 2024 links metformin risk to accumulation during impaired kidney function and tissue hypoxia. The prescriber also considers liver disease, alcohol intake, heart failure, and the complete medicine list.
Yes. Diarrhoea is a recognised metformin adverse effect and can occur with nausea, cramping, bloating, or a metallic taste. NHS clinical information reviewed in 2023 describes taking metformin with meals and gradual dose adjustment as practical ways to improve tolerance. Severe or persistent diarrhoea is different because dehydration can reduce kidney function and increase metformin exposure.
Metformin may be prescribed for some adolescents with type 2 diabetes, but treatment depends on age, diagnosis, kidney function, and specialist assessment. It is not appropriate to give an adult’s tablets to a child without a specific prescription. NICE guidance in 2022 described metformin as part of paediatric type 2 diabetes care in selected circumstances. A child with excessive thirst, frequent urination, weight loss, vomiting, or drowsiness needs prompt clinical assessment.
Severe weakness, deep or rapid breathing, repeated vomiting, severe abdominal pain, confusion, faintness, or feeling unusually cold can indicate lactic acidosis and require urgent medical attention. Loss of consciousness, seizure, or inability to swallow during suspected hypoglycaemia also requires emergency help. EMA safety information reviewed in 2018 identifies lactic acidosis as a rare but serious metformin-associated reaction. Do not take another dose while seeking urgent assessment if these symptoms occur.
Glucophage is usually taken with or immediately after food because this can reduce nausea, diarrhoea, and abdominal discomfort. The exact timing follows the prescribed schedule, especially when the formulation is modified-release. NHS advice reviewed in 2023 supports taking metformin with meals to improve gastrointestinal tolerance. Taking an extra tablet because a meal was larger than usual is not appropriate.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
The first ten days brought loose stools and a metallic taste. Taking it after food helped, and the stomach problems became much less noticeable. My morning readings improved gradually rather than overnight.
It fitted easily into my routine, and I did not have any low readings from it alone. I still had bloating on some days, especially after a large meal, so the timing mattered more than I expected.
My glucose improved, but I had two episodes of sweating and shaking after changing my other medicine. The metformin was not the only treatment involved, and the medication review helped identify the problem.
The tablets were manageable with meals, although diarrhoea returned during a stomach infection. I paused the next dose only after receiving specific sick-day advice and arranged a kidney-function check.
